8.30 - heck, i sold at 14 way back in early 2012 just after they released ph III data. glad i did, as i had bought at 8 right after the IPO. this has the writing on the wall - it's a good drug with a poorly designed ph III that yielded mixed results. FDA need not approve - despite some safety advantage - given already useful RCC drugs on the market. Big risk in holding at this point, in my view, just gambling.